Hikma signs exclusive licensing agreement with pharma& to bring innovative oncology treatment to MENA
By Editor_wr On Apr 10, 2025
Hikma Pharmaceuticals PLC (Hikma), the multinational pharmaceutical company, has announced an exclusive licensing agreement with pharmaand GmbH (pharma&), a global pharmaceutical company based in Vienna, Austria.
This agreement grants Hikma exclusive rights to commercialise rucaparib across the Middle East and North Africa (MENA) region. Rucaparib, marketed as Rubraca®, is an innovative small-molecule oral therapy designed to inhibit poly (ADP-ribose) polymerases (PARPs), a family of proteins critical to DNA repair in cancer cells. This mechanism makes rucaparib an important treatment option for patients battling ovarian cancer, the 8th most common cancer in women globally[1], and prostate cancer, the 4th most common cancer worldwide and the second most common cancer in men[2].
Rucaparib has received regulatory approval from both the European Medicines Agency (EMA) and the United States Food and Drug Administration (U.S. FDA).
Mazen Darwazah, Hikma's Executive Vice Chairman and President of MENA, said: 'We are pleased to add rucaparib, an innovative oncology treatment, to our growing oncology portfolio in MENA. This agreement is a major step to further enhance patients' access to life-changing treatments and address critical medical needs across the region. By strengthening our oncology portfolio, we reaffirm our commitment to providing advanced cancer treatments and supporting our purpose of putting better health within reach, every day.'
As the company's first innovative small-molecule oral therapy in oncology approved by both the U.S. FDA and EMA, this partnership strengthens Hikma's promise of providing better access to life saving treatment options and its commitment to improving patient outcomes.
[1] Ovarian cancer statistics | World Cancer Research Fund
[2] Prostate cancer statistics | World Cancer Research Fund
Comments are closed.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Web Release
4 days ago
- Web Release
Fresh Del Monte Brings Its Iconic Pinkglow® Pineapple to the UAE, Redefining the Premium Fruit Market
Fresh Del Monte Produce Inc . (NYSE: FDP), a global leader in fresh produce and the world's only grower of the patented Pinkglow® pineapple, is expanding the global footprint of its premium pink-fleshed fruit with an exclusive launch in the United Arab Emirates. Beginning June 4, consumers in the UAE can purchase Pinkglow® pineapples only on talabat mart, the quick-commerce arm of talabat, the leading on-demand delivery platform in the MENA region. With its vibrant pink interior, delicate sweetness, and striking presentation, Pinkglow® pineapple has captivated global audiences since its debut. The pineapple is the result of over 16 years of research and development and is exclusively grown in Costa Rica and distributed by Fresh Del Monte, whose vertically integrated operations ensure rigorous quality, sustainability, and flavor standards from field to shelf. Until now, the Pinkglow® pineapple has only been available in select markets across North America and Asia, making its arrival in the UAE a major milestone in its global expansion. In the UAE, the Pinkglow® pineapple will be: Available only on talabat mart for six months. Sold in limited quantities weekly. Priced at AED 125 (approx. USD 34), positioning it as a premium fruit experience. Delivered in bespoke packaging, reinforcing its status as a giftable, must-try delicacy. 'This launch is a continuation of our mission to reimagine how the world experiences pineapples,' said Racha El Aawar, Fresh Del Monte's Director of Regional Marketing in the Middle East. 'We're not just selling fruit—we're curating indulgent, memorable moments rooted in decades of agricultural innovation. talabat mart's reach and cultural resonance in the UAE make them the perfect partner to introduce the Pinkglow® pineapple to consumers in the Middle East.' Alix Julien de Zelicourt, General Manager, talabat mart said, 'At talabat mart, we take pride in consistently unearthing unique and premium products for our customers; a true reflection of our pioneering spirit. The Pinkglow® pineapple celebrates this: bold, vibrant, and extraordinary. We're proud to be the only platform bringing this iconic fruit to customers in the UAE.' Since its debut, Pinkglow® pineapples have become a global phenomenon, embraced by celebrities, tastemakers, influencers, and event planners for their visually stunning pink flesh and vibrant aesthetic. Whether served at luxury brunches, styled on social feeds, or gifted as a statement piece, Pinkglow® pineapple delivers both flavor and flair. Today, Fresh Del Monte remains the unrivaled leader in the global pineapple category, offering proprietary varieties like Honeyglow® pineapples, Rubyglow® pineapples, Pinkglow® pineapples, and the DM Zero® pineapple—each designed to elevate taste, appearance, and appeal to different consumers. The company's vertically integrated model enables rapid innovation and quality control across the supply chain, responding to evolving consumer preferences with unmatched agility.
TECHx
6 days ago
- TECHx
Check Point Launches Quantum Smart-1 Appliances
Home » Emerging technologies » Cyber Security » Check Point Launches Quantum Smart-1 Appliances Check Point® Software Technologies Ltd. (NASDAQ: CHKP) has announced the launch of its next-generation Quantum Smart-1 Management Appliances. The company is a global leader in cybersecurity solutions. The new appliances deliver a 2X increase in managed gateways. They also offer up to 70% higher log processing speeds. These improvements are designed to meet the complex demands of hybrid enterprises. Check Point revealed that the appliances are fully integrated into the Check Point Infinity Platform. This integration enhances threat detection and response using a hybrid mesh architecture. It also supports connections with over 250 third-party solutions. Nataly Kremer, Chief Product Officer at Check Point, stated that security teams are under pressure from AI-generated threats and fragmented infrastructures. She said the new appliances simplify these challenges through AI, automation, and precision. The rise of remote work and distributed teams has increased vulnerabilities. Check Point Research reported that AI services are now used in over 51% of enterprise networks each month. This growth widens security risks, making advanced security policies essential. According to Check Point, the Quantum Smart-1 Management Appliances help security teams operate faster and smarter across on-premises, cloud, and remote environments. Key features include: Managing up to 10,000 gateways, enabling scale without rearchitecting. Achieving up to 70% higher log speeds for faster threat response. Storing up to 70TB of logs locally to meet compliance needs. The appliances unify security operations and reduce complexity in hybrid environments. They are available in five models, including the high-performance 7000 Ultra. Check Point confirmed that the new models support tools like Infinity AI Copilot, Playblocks, Policy Advisor, Compliance, and Infinity AIOps. These tools streamline policy and firewall management. Miercom recently named Check Point the top performer in its AI-Powered Cyber Security Platform Benchmark. The report recognized Check Point's superior management usability and threat prevention. Rob Smithers, CEO of Miercom, said Check Point's Infinity Platform outperformed its peers. He added that its AI-driven design and hybrid mesh model set a new standard in cybersecurity. Check Point continues to advance cybersecurity with AI-powered solutions tailored for modern enterprise needs.
Al Etihad
6 days ago
- Al Etihad
M42, AstraZeneca, SOPHiA GENETICS to transform cancer diagnosis, care
3 June 2025 14:30 ABU DHABI (ALETIHAD)M42, a global health leader powered by technology, announced a strategic collaboration with AstraZeneca and SOPHiA GENETICS to bring cutting-edge liquid biopsy testing to the UAE, aimed at advancing cancer diagnosis, informing treatment decisions, and enabling faster, accurate biomarker testing across a broad range of part of the collaboration, M42 will integrate SOPHiA GENETICS' MSK-ACCESS®, powered with SOPHiA DDM™ technology, into its testing infrastructure, enabling non-invasive genomic profiling of cancers through a simple blood approach does not replace but rather complements routine cancer screenings, and is designed for patients who are unable to undergo a solid tumor biopsy, enabling them to be matched with a precision therapy tailored to their specific cancer the next 12 months, the partnership will enable liquid biopsy testing access across select leading hospitals across the UAE, providing patients with faster, less invasive biomarker insights compared to traditional tissue biopsies, while also strengthening testing infrastructure and capabilities for a wide range of cancers in the new testing programme will initially target lung, ovarian, breast, colorectal, and pancreatic cancers, among others, addressing some of the most critical cancer burdens in the studies are set to commence shortly at Cleveland Clinic Abu Dhabi, marking a key milestone toward the full clinical launch planned for the latter part of Q2 El-khani, Senior Vice President, Operations, Integrated Health Solutions at M42, said, 'This collaboration reflects our vision of democratising health by making advanced diagnostics accessible to more patients, supporting not just early diagnosis but also real-time treatment monitoring and cost-effective, precise, predictive, and personalised care.'Sameh El Fangary, Cluster President GCC of AstraZeneca, stated, "Our work, and our collaborations with partners across industry, are driving towards better treatments for patients as well as a more sustainable future for healthcare systems. Through our latest partnerships, we are committed to transforming cancer care for millions in the region by advancing early diagnosis and optimising patient pathways from detection to therapy.' Ross Muken, President of SOPHiA GENETICS, said, "Expanding access to advanced testing technologies is central to our mission at SOPHiA GENETICS. Partnering with M42 and AstraZeneca in the UAE allows us to equip healthcare providers with the tools they need to personalise care, monitor disease in real-time, and ultimately improve outcomes for patients across the region." Source: Aletihad - Abu Dhabi
